Brief: Piramal Pharma Says US FDA Conducted Gmp Inspection Of Co's Bethlehem Facility From Sept 18 To Sept 27
28/09/2023 14:54
Sept 28 (Reuters) - Piramal Pharma Ltd PIRM.NS :
* US FDA CONDUCTED GMP INSPECTION OF CO'S BETHLEHEM FACILITY
FROM
SEPT 18 TO SEPT 27
* ON CONCLUSION OF INSPECTION, A FORM-483 WAS ISSUED WITH 2
OBSERVATIONS
Source text for Eikon: ID:nBSE3dDMh5
Further company coverage: PIRM.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Piramal Pharma (Mumbai)
See all newsBrief: Piramal Pharma Receives Permanent Revocation Of Closure Order For Dahej Site
Brief: Piramal Pharma Solutions Announces Partnership With Botanix To Support Drug Substance Development
Brief: Piramal Pharma Announces Successful Closure Of Us FDA Inspection At Digwal Facility
India's Piramal Pharma eyes complex drug demand for earnings boost, chair says
Brief: Piramal Pharma Says Closure Of US FDA Inspection At Manufacturing Facility At Lexington